ImmunoPrecise Antibodies lines up acquisition of Dutch biotech

Crossbeta has developed an innovative technology to generate stable oligomers for drug discovery and development in disease areas characterized by the presence of misfolded proteins, such as Alzheimer’s, Parkinson’s and Huntington’s disease
Alzheimer's disease affects neural pathways
Crossbeta's technology has already yielded multiple antibodies with biomarker/diagnostic and therapeutic potential for Alzheimer's and Parkinson's disease

ImmunoPrecise Antibodies Ltd (CVE:IPA) is lined up to acquire Crossbeta Biosciences, a Dutch company with a proprietary technology for efficient oligomer-based drug discovery.

The €8.5mln (C$12.84mln) acquisition, should it go ahead, would allow ImmunoPreceise Anitbodies (IPA) to build a pipeline of antibodies with applications in biomarker/diagnostic assays and antibody solutions therapeutics.

IPA will either pay for the acquisition through the issue of shares or the use of convertible notes carrying a coupon of 6%.

The Canadian company has also indicated it would pump €15mln (C$22.65mln) into the company, with some of that planned investment triggered by milestone achievements.

IPA said the purchase of the privately-held company would significantly further its ambition of becoming a single-source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and of offering the full spectrum of antibody production methodologies (library-based technologies, hybridoma methods, transgenic animal based platforms and single B cell-based technology).

Furthermore, the acquisition enhances the company's source of, and capacity for, developing unique antigens for generating and selecting antibodies.

"In acquiring Crossbeta Biosciences BV, IPA becomes a leading integrated antibody solutions company with high-value potential biomarker/diagnostic and therapeutic assets," said James Kuo, the chairman and interim president of the company.

View full IPA profile View Profile

Immunoprecise Antibodies Ltd Timeline

Related Articles

cancer cell
January 31 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
Zelda's Stewart Washer at Proactive's CEO Sessions
November 16 2017
Stewart Washer at Proactive's CEO Sessions this week.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © 2ndrangers.us, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.